On April 15, 2026, Aurora Cannabis Inc. (NASDAQ: ACB) (TSX: ACB) announced that it had acquired Safari Flower Company, an established EU GMP certified cannabis cultivator and manufacturer. Aggregate consideration is valued at $26.5 million, subject to customary adjustments, and inclusive of a cash payment of $2 million that is contingent on satisfaction of certain conditions.
As consideration, Aurora issued 2,417,180 common shares and paid $15 million in cash, subject to customary adjustments post-closing.
Safari Flower’s 59,000 square foot, purpose-built EU GMP certified indoor cultivation and manufacturing facility in Ontario will provide Aurora with incremental capacity that is closely aligned with its existing cultivation and manufacturing sites. The acquisition is expected to deliver positive EBITDA contributions in 2027, with incremental benefits over time as the operations are optimized within Aurora’s supply network.
Commenting on the transaction, Miguel Martin, Executive Chairman and CEO of Aurora, said:
“The acquisition of Safari Flower Company marks an important milestone for Aurora as we continue to purposefully invest in expanding our EU GMP capacity to support the rapidly growing international medical cannabis market. We intend to leverage our extensive plant science and operational expertise to increase the supply of high quality, EU GMP manufactured flower that further enhances our leadership in these expanding, high margin and highly regulated markets. An enhanced supply chain will enable us to capture greater international market share while delivering superior quality and value to our most respected patients worldwide.”
Fort Capital Partners acted as financial advisor to Aurora on this transaction.